S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Stereotaxis, Inc. (STXS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.7500 |
| Open | 1.8100 |
| Bid | 1.7900 x 800 |
| Ask | 1.8000 x 1000 |
| Day's Range | 1.7800 - 1.8250 |
| 52 Week Range | 1.7200 - 10.3000 |
| Volume | |
| Avg. Volume | 408,959 |
| Market Cap | 133.5M |
| Beta (5Y Monthly) | 1.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1310 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.67 |
- Motley Fool
Stereotaxis (STXS) Q1 2022 Earnings Call Transcript
Thank you for joining us for Stereotaxis first quarter 2022 earnings conference call. On the heels of last year, where we demonstrated a restart in capital adoption and overall sales growth, our primary challenge has been driving consistent momentum and growth in capital activity.
- Zacks
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Stereotaxis Reports 2022 First Quarter Financial Results
ST. LOUIS, May 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2022. “Stereotaxis demonstrated continued progress on capital adoption despite a challenging macro environment,” said David Fischel, Chairman and CEO. “We are focused on improving our internal commercial capabilities while navigating the external challenges an
